Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: Possible effect of age, liver disease and length of therapy

British Journal of Clinical Pharmacology

Volumn 47, Issue 1, 1999, Pages 115-119

  Kimura, Miyuki ^b   Ieiri, Ichiro ^a   Wada, Yukiko ^b   Mamiya, Kohsuke ^b   Urae, Akinori ^b   Iimori, Emiko ^b   Sakai, Terufumi ^b   Otsubo, Kenji ^b   Higuchi, Shun ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b NONE

Author keywords

Clinical applicability; CYP2C19; Genotype; Omeprazole hydroxylation index; Phenotype

Indexed keywords

OMEPRAZOLE; STOMACH SECRETION INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CODON; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; EXON; GENOTYPE; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PHENOTYPE; PRIORITY JOURNAL; RELIABILITY;

ADULT; AGE FACTORS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; HYDROXYLATION; LIVER DISEASES; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PEPTIC ULCER; PHENOTYPE; TIME FACTORS;

EID: 0013389471     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00858.x     Document Type: Article

References (21)

1. 1 Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25-31.
2. 2 Andersson T, Miners JO, Veronese M, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36; 521-530.
3. 3 Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57: 662-669.
4. 4 Curi-Pedrosa R, Pichard L, Bonfils C, Jacoz-Aigrain E, Maurel P. Major implication of cytochrome P4503A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. Br J Clin Pharmacol 1993; 36: 156p.
5. 5 Chang M, Dahl M-L, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-363.
6. 6 Chang M, Tybring G, Dahl M-L, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omepraaole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-518.
7. 7 Roh H-K, Dahl M-L, Tybring G, Yamada H, Cha Y-N, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996; 6: 547-551.
8. 8 Ieiri I, Kubota T, Urae A, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996; 59: 647-653.
9. 9 de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in human. J Biol Chem 1994; 269: 15419-15422.
10. 10 de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
11. 11 Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9, in a Japanese population. Ther Drug Monit 1998; 20: 243-247.
12. 12 Xiao Z-S, Goldstein JA, Xie H-G, et al. Difference in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281: 604-609.
13. 13 Ferguson RJ, de Morais SMF, Benhamou S, et al. A new genetic defect in human CYP2C19: Mutation of the initial codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284: 356-361.
14. 14 Relling MV, Ayers D, Heideman RL. Mephenytoin phenotyping: lack of haematologic effect and timing of urine collections. Pharmacogenetics 1991; 1: 42-49.
15. 15 Xie H-G, Huang S-L, Xu Z-H, Xiao Z-S, He N, Zhou H-H. Evidence for the effect of gender on activity of (S)-mephenytoin 4′-hydroxylasc (CYP2C19) in a Chinese population. Pharmacogenetics 1997; 7: 115-119.
16. 16 Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195-212.
17. 17 Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
18. 18 Andersson T, Olsson R, Regardh C-G, Skanberg I.
19. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. Clin Pharmacokinet 1993; 24: 71-78.
20. 19 Landahl S, Andersson T, Larsson M, et al. Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin Pharmacokinet 1992; 23: 469-476.
21. 20 Brockmoller J, Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994; 27: 216-248.